Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 29, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

July 31, 2026

Conditions

Neuroendocrine Carcinoma

Interventions

BIOLOGICAL

ZG006

ZG006 will be administered as an intravenous (IV) infusion.

Trial Locations (1)

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY